Abstract
There are no validated markers for predicting benefit from angiogenesis inhibitors or classifying tumors with distinct angiogenic phenotypes. In patients with non-small cell lung cancer treated with bevacizumab and erlotinib, Franzini and colleagues find that angiogenesis- and hypoxia-associated gene expression signatures predict tumor response and/or clinical outcome, and may define distinct angiogenic patterns.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 5188-5190 |
| Number of pages | 3 |
| Journal | Clinical Cancer Research |
| Volume | 21 |
| Issue number | 23 |
| DOIs | |
| State | Published - Dec 1 2015 |
ASJC Scopus subject areas
- Oncology
- Cancer Research